-
Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-18 Yasser Fouad, Salma Barakat, Almoutaz Hashim, Hasmik Ghazinyan
Fatty liver disease is one of the most common liver diseases in the Middle East and North Africa region, and globally. Unfortunately, there is a lack of awareness regarding this condition. The nomenclature changes for NAFLD (to MAFLD or MASLD) have gained considerable attention in the hepatology community. Here, we present our point of view on this ongoing change and debate.
-
Future direction of total neoadjuvant therapy for locally advanced rectal cancer Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-14 Yoshinori Kagawa, J. Joshua Smith, Emmanouil Fokas, Jun Watanabe, Andrea Cercek, Florian R. Greten, Hideaki Bando, Qian Shi, Julio Garcia-Aguilar, Paul B. Romesser, Natally Horvat, Hanna Sanoff, William Hall, Takeshi Kato, Claus Rödel, Arvind Dasari, Takayuki Yoshino
-
Cell senescence in liver diseases: pathological mechanism and theranostic opportunity Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-14 David Sanfeliu-Redondo, Albert Gibert-Ramos, Jordi Gracia-Sancho
-
ECCO’24 Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-13 Katrina Ray
In February 2024, Nature Reviews Gastroenterology & Hepatology attended the 19th Congress of ECCO (ECCO’24) in Stockholm, Sweden. The meeting, according to the organizers, had >7,200 participants (represented by 99 countries) and focused on inflammatory bowel disease (IBD), with this year’s congress theme being ‘Crossing Borders in IBD’. The ‘crossing borders’ theme tied well with the new REACH strategy
-
Screening for liver fibrosis: lessons from colorectal and lung cancer screening Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-13 Maja Thiele, Patrick S. Kamath, Isabel Graupera, Antoni Castells, Harry J. de Koning, Miquel Serra-Burriel, Frank Lammert, Pere Ginès
-
Inconsistencies in the predictive value of PD-L1 in metastatic gastroesophageal cancer Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-13 Raghav Sundar, Elizabeth C Smyth
-
Reply to: “irLI or Not irLI: That is the Question” J. Hepatol. (IF 25.7) Pub Date : 2024-03-13 Ciro Celsa, Giuseppe Cabibbo, David James Pinato
-
Expanding the Dialogue: A Closer Look at AIH Management and HCC Risk J. Hepatol. (IF 25.7) Pub Date : 2024-03-13 Dan Shan PhD
-
Letter to the Editor: The MAFLD and MASLD Conundrum: Is It Reinvention Of The Wheel? J. Hepatol. (IF 25.7) Pub Date : 2024-03-13 Mariana M. Ramírez-Mejía, Mohammed Eslam, Nahum Méndez-Sánchez
-
Esophageal Enigma: Isolated Lower Esophageal Sphincter Amyloidosis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-13 Alam Merchant M.D, Raul S. Gonzalez M.D, Anand Jain M.D
-
Validation of the THCC-RI predictive model for hepatocellular carcinoma in Asian cohort Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-13 Jeong-Ju Yoo, Young-Gi Song, Ji Eun Moon, Young Seok Kim, Sang Gyune Kim
-
Risk of Cancer in Patients with Diverticular Disease: A Population-based Cohort Study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-13 Frederikke S. Troelsen, Dóra K. Farkas, Rune Erichsen, Lisa L. Strate, John A. Baron, Henrik T. Sørensen
Several studies have investigated the association between diverticular disease (DD) and colorectal cancer. However, whether there is an association between DD and malignancies other than those in the colorectum remains uncertain. For the 1978-2019 period, we conducted a nationwide, population-based cohort study using national Danish healthcare data. We followed DD patients for up to 20 years, beginning
-
Group 3 innate lymphoid cells in intestinal health and disease Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-11 Veronika Horn, Gregory F. Sonnenberg
-
Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis J. Hepatol. (IF 25.7) Pub Date : 2024-03-11 Ann Thu Ma, Cristina Solé, Adrià Juanola, Laia Escudé, Laura Napoleone, Emma Avitabile, Martina Pérez-Guasch, Marta Carol, Enrico Pompili, Jordi Gratacós-Ginés, Anna Soria, Ana Belén Rubio, Marta Cervera, Maria José Moreta, Manuel Morales, Elsa Solà, Esteban Poch, Núria Fabrellas, Isabel Graupera, Elisa Pose, Pere Ginès
The management of acute kidney injury (AKI) in cirrhosis is challenging. The EASL guidelines proposed an algorithm, but this has never been validated. We aimed to prospectively evaluate this algorithm in clinical practice. Prospective cohort study of consecutive hospitalized patients with cirrhosis and AKI. EASL management algorithm includes identification/treatment of precipitating factors, 2-day
-
Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta J. Hepatol. (IF 25.7) Pub Date : 2024-03-11 Mathias JACHS M.D. Ph.D., Lisa SANDMANN M.D., Lukas HARTL M.D., Tammo TERGAST M.D., Michael SCHWARZ M.D., David Josef Maria BAUER M.D., Lorenz BALCAR M.D., Alena EHRENBAUER, Benedikt Silvester HOFER M.D., Markus CORNBERG M.D., Henrike LENZEN M.D., Katja DETERDING M.D., Michael TRAUNER M.D., Mattias MANDORFER M.D. Ph.D., Heiner WEDEMEYER M.D., Thomas REIBERGER M.D., Benjamin MAASOUMY M.D.
Non-invasive tests (NIT) for clinically significant portal hypertension (CSPH) in compensated advanced chronic liver disease (cACLD) lack validation in patients infected with hepatitis D virus (HDV). HDV-cACLD patients (LSM ≥10 kPa or histological METAVIR F3/F4 fibrosis) who underwent paired HVPG and NIT assessment at Medical University of Vienna or Hannover Medical School between 2013 and 2023 were
-
One-year transplant-free survival following hospital discharge after ICU Admission for ACLF in the Netherlands J. Hepatol. (IF 25.7) Pub Date : 2024-03-11 Jubi de Haan, Fabian Termorshuizen, Nicolette de Keizer, Diederik Gommers, Caroline den Hoed
Patients with acute decompensated (AD) liver cirrhosis or acute-on-chronic liver failure (ACLF) often require intensive care unit (ICU) admission for organ support. Existing research, mostly from specialized liver transplant centers, largely addresses short-term outcomes. Our aim was to evaluate in-hospital mortality and 1-year transplant-free survival after hospital discharge in the Netherlands. We
-
Efficacy of Stereotactic Ablative Radiotherapy in Patients with Oligometastatic Hepatocellular Carcinoma: A Phase II Study J. Hepatol. (IF 25.7) Pub Date : 2024-03-11 Seo Hee Choi, Byung min Lee, Jina Kim, Do Young Kim, Jinsil Seong
Stereotactic ablative radiotherapy (SABR) has demonstrated curative potential with survival benefits in patients with oligometastatic disease (OMD). However, limited evidence exists regarding its use in oligometastatic hepatocellular carcinoma (HCC). We aimed to prospectively investigate the efficacy and safety of SABR in patients with oligometastatic HCC. We enrolled patients with controlled primary
-
Long-Term Proton Pump Inhibitor Use: Review of Indications and Special Considerations Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-10 Amrit K. Kamboj, Dhyanesh A. Patel, Rena Yadlapati
-
2023 FDA approvals in gastroenterology and hepatology Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-07 Eleni Kotsiliti
In 2023, the Center for Drug Evaluation and Research (CDER) of the US Food and Drug Administration (FDA) approved 55 novel drugs, 4 related to gastroenterology and hepatology. In 2022, the new drug approvals included treatments for Helicobacter pylori infection, T2DM blood sugar control in addition to diet and exercise, FGFR2-aberrant intrahepatic cholangiocarcinoma and unresectable hepatocellular
-
Pkd1l1-deficiency drives biliary atresia through ciliary dysfunction in biliary epithelial cells J. Hepatol. (IF 25.7) Pub Date : 2024-03-08 Yi Zou Lim, Min Zhu, Yunguan Wang, Tripti Sharma, Shannon Kelley, Estelle Oertling, Hao Zhu, Natasha Corbitt
Syndromic biliary atresia is a cholangiopathy characterized by fibro-obliterative changes in the extrahepatic bile duct (EHBD) and congenital malformations including laterality defects. The aetiology remains elusive and faithful animal models are lacking. Genetic syndromes provide important clues for underlying pathogenic mechanisms of disease. We investigated the role of the gene in syndromic biliary
-
Endothelial POFUT1 controls injury-induced liver fibrosis by repressing fibrinogen synthesis J. Hepatol. (IF 25.7) Pub Date : 2024-03-07 Shan He, Yuru Luo, Wangge Ma, Xiaoke Wang, Chengrong Yan, Wenyang Hao, Yuan Fang, Hongyu Su, Baochang Lai, Junhui Liu, Ying Xiong, Ting Bai, Xiaoyong Ren, Enqi Liu, Hua Han, Yue Wu, Zuyi Yuan, Yidong Wang
NOTCH signaling in liver sinusoidal endothelial cells (LSECs) regulates liver fibrosis, a pathological feature of chronic liver diseases. POFUT1 is an essential regulator of NOTCH signaling. Here, we investigated the role of LSECs-expressed POFUT1 in liver fibrosis. Endothelial-specific knockout mice were generated and subjected to experimental liver fibrosis by chronic carbon tetrachloride exposure
-
Van Gogh-like 2 is essential for the architectural patterning of the mammalian biliary tree. J. Hepatol. (IF 25.7) Pub Date : 2024-03-07 Michaela Raab, Ersi Christodoulou, Roopesh Krishnankutty, Andreea Gradinaru, Alexander Daniel Walker, Paula Olaizola, Nicholas Thomas Younger, Anabel Martinez Lyons, Edward Joseph Jarman, Konstantinos Gournopanos, Alexander von Kriegsheim, Scott Hamilton Waddell, Luke Boulter
In the developing liver, bipotent epithelial progenitor cells known as hepatoblasts undergo lineage segregation to form the two major epithelial cell types, hepatocytes that constitute the bulk of the liver parenchyma and biliary epithelial cells (cholangiocytes) which comprise the bile duct, a complex tubular network which is critical for normal liver function. Notch and TGFβ signalling promote the
-
Cutting edges in the HBV genome: How RNA splicing is involved in modulating virus ultrastructure to promote infection J. Hepatol. (IF 25.7) Pub Date : 2024-03-07 Stefan Seitz, Ralf Bartenschlager
-
Syngeneic Murine Models with Distinct Immune Microenvironments Represent Subsets of Human Intrahepatic Cholangiocarcinoma J. Hepatol. (IF 25.7) Pub Date : 2024-03-07 Jennifer L. Tomlinson, Binbin Li, Jingchun Yang, Emilien Loeuillard, Hannah E. Stumpf, Hendrien Kuipers, Ryan Watkins, Danielle M. Carlson, Jessica Willhite, Daniel R. O’Brien, Rondell P. Graham, Xin Chen, Rory L. Smoot, Haidong Dong, Gregory J. Gores, Sumera I. Ilyas
Cholangiocarcinoma (CCA) is a poorly immunogenic malignancy with limited survival. Syngeneic, immunocompetent mouse models of CCA are an essential tool to elucidate the tumor immune microenvironment (TIME), understand mechanisms of tumor immune evasion, and test novel immunotherapeutic strategies. The scope of this study was to develop and characterize immunocompetent CCA models with distinct genetic
-
-
You Are What You Eat: a Twin Experiment Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 H, o, l, l, i, e, , S, h, e, r, w, o, o, d, -, M, a, r, t, i, n
-
Research in Brief Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 H, o, l, l, y, , B, a, k, e, r
-
Resmetirom for NASH: balancing promise and prudence Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 T, h, e, , L, a, n, c, e, t, , G, a, s, t, r, o, e, n, t, e, r, o, l, o, g, y, , &, , H, e, p, a, t, o, l, o, g, y
-
Gluten and non-coeliac gluten sensitivity: the nocebo effect and future avenues – Authors' reply Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Marlijne C G de Graaf, Daniel Keszthelyi, Fred J P H Brouns, Louise Dye, Daisy M A E Jonkers, on behalf of all authors
-
The DESTIN trial: to step up or not? – Authors' reply Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Ji Young Bang, Shyam Varadarajulu
-
The DESTIN trial: to step up or not? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Oscar Cahyadi, Vinay Dhir, John Leeds, Enrique de-Madaria, Nadeem Tehami
-
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions – Authors' reply Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Xiang-Lei Yuan, Bing Hu
-
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Daisuke Murakami, Masayuki Yamato, Takayoshi Nishino, Makoto Arai
-
The DESTIN trial: to step up or not? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Avinash Tiwari, Mayank Mehrotra, Ajmal Hasan, Jaya Agarwal, Gaurav Kumar Singh
-
Gluten and non-coeliac gluten sensitivity: the nocebo effect and future avenues Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Maurizio Mennini, Federica Ferrari, Pasquale Parisi, Giovanni Di Nardo
-
The Synergism of Public Health Policies and Social Work May Reduce Mortality from Cancer, Liver Disease and Cardiovascular Disease J. Hepatol. (IF 25.7) Pub Date : 2024-03-06 Shijie GUO, Jingqiang ZENG
-
Reply to: “Familial clustering of MASLD: Rethinking strategies for population screening” J. Hepatol. (IF 25.7) Pub Date : 2024-03-06 Fahim Ebrahimi, Jonas F. Ludvigsson
-
Uric acid in pediatric MASLD definition: Is it time to implement diagnostic criteria? J. Hepatol. (IF 25.7) Pub Date : 2024-03-06 Anna Di Sessa, Stefano Guarino, Giuseppina Rosaria Umano, Emanuele Miraglia del Giudice, Pierluigi Marzuillo
-
Rare monogenic causes of steatotic liver disease masquerading as MASLD J. Hepatol. (IF 25.7) Pub Date : 2024-03-06 Martijn CGJ. Brouwers, David Cassiman
-
Autoimmune Hepatitis: Mycophenolate mofetil versus azathioprine as first line therapy J. Hepatol. (IF 25.7) Pub Date : 2024-03-06 Cem Şimşek MD, Staffan Wahlin MD, Cumali Efe MD
-
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-04 Stephen A. Harrison, Juan P. Frias, K. Jean Lucas, Gary Reiss, Guy Neff, Sureka Bollepalli, Yan Su, Doreen Chan, Erik J. Tillman, Ali Moulton, Brittany de Temple, Arian Zari, Reshma Shringarpure, Timothy Rolph, Andrew Cheng, Kitty Yale
In phase 2 studies, efruxifermin, an Fc–FGF21 analog, significantly reduced steatohepatitis and fibrosis in patients with non-alcoholic steatohepatitis (NASH), now called metabolic dysfunction-associated steatohepatitis (MASH), for which there is no approved treatment. Type 2 diabetes (T2D) and obesity are prevalent among patients with MASH and increasingly treated with glucagon-like peptide-1 receptor
-
Prevalence of Gastric Precursor Lesions in Countries with Differential Gastric Cancer Burden: A Systematic Review & Meta-Analysis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-02 Duco T. Mülder, Anne I. Hahn, Robert J. Huang, Margaret J. Zhou, Benjamin Blake, Omonefe Omofuma, John D. Murphy, Daniela S. Gutiérrez-Torres, Ann G. Zauber, James F. O’Mahony, M. Constanza Camargo, Uri Ladabaum, Jennifer M. Yeh, Chin Hur, Iris Lansdorp-Vogelaar, Reinier Meester, Monika Laszkowska
The prevalence of precursor lesions for gastric cancer (GC) and the differential burden between countries of varying GC risk is not well understood. We conducted a systematic review and meta-analysis to estimate the global prevalence of precursor lesions. We estimated the prevalence of atrophic gastritis (AG), gastric intestinal metaplasia (IM), and dysplasia in regions with low, medium, and high-GC
-
The Efficacy of Real-Time Computer-Aided Detection of Colonic Neoplasia In Community Practice: A Pragmatic Randomized Controlled Trial. Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-02 Nikhil R. Thiruvengadam MD, Pejman Solaimani MD, Manish Shrestha MD, Seth Buller, Rachel Carson PA, Breanna Reyes-Garcia PA, Ronaldo D. Gnass MD, Bing Wang MD PhD, Natalie Albasha BS, Paul Leonor MD, Monica Saumoy MD MS, Raul Coimbra MD, Arnold Tabuenca MD, Wichit Srikureja MD, Steve Serrao MD MPH PhD
The use of computer-aided detection (CADe) has increased the adenoma detection rates (ADR) during colorectal cancer (CRC) screening/surveillance in randomized controlled trials (RCT) but has not shown benefit in real-world implementation studies. We performed a single-center pragmatic RCT to evaluate the impact of real-time CADe on ADR in colonoscopy performed by community gastroenterologists. We enrolled
-
The Management of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-29 Jordan E. Axelrad MD MPH, David T. Rubin MD
-
Multi-omics characterization of healthy and PSC human liver – what we knew and what we have learned J. Hepatol. (IF 25.7) Pub Date : 2024-02-28 Jenny Krause, Christoph Schramm
-
Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease J. Hepatol. (IF 25.7) Pub Date : 2024-02-28 Katrine Holtz Thorhauge, Georg Semmler, Stine Johansen, Katrine Prier Lindvig, Maria Kjærgaard, Johanne Kragh Hansen, Nikolaj Torp, Camilla Dalby Hansen, Peter Andersen, Benedikt Silvester Hofer, Wenyi Gu, Mads Israelsen, Mattias Mandorfer, Thomas Reiberger, Jonel Trebicka, Maja Thiele, Aleksander Krag
Liver stiffness measurements (LSM) are recommended for disease prognostication and monitoring. We evaluated if LSM, using transient elastography, and LSM changes predict decompensation and mortality in patients with alcohol-related liver disease (ALD). Observational cohort study of compensated patients at risk of ALD from Denmark and Austria. We evaluated the risk of decompensation and all-cause mortality
-
Multidrug-resistant bacterial infections after liver transplantation: prevalence, impact, and risk factors J. Hepatol. (IF 25.7) Pub Date : 2024-02-28 Rosa Martin-Mateos, Laura Martínez-Arenas, Ángela Carvalho-Gomes, Laia Aceituno, Valle Cadahía, María Magdalena Salcedo, Ana Arias, Sara Lorente Pérez, Aitor Odriozola, Javier Zamora, Marino Blanes, Óscar Len, Laura Benítez, Isabel Campos-Varela, María Luisa González Diéguez, Diego Rojo Lázaro, Jesús Fortún, Antonio Cuadrado, Natalia Marcos Carrasco, Manuel Rodríguez-Perálvarez, Carmen Navascues, Emilio
Multidrug-resistant (MDR) bacterial infections are an increasing healthcare problem worldwide. This study analyzes the incidence, burden, and risk factors associated with MDR infections after liver transplantation (LT). This retrospective, multicenter cohort study included adult patients who underwent LT between January 2017 and January 2020. Risk factors related to pre-LT disease, surgical procedure
-
Single cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity J. Hepatol. (IF 25.7) Pub Date : 2024-02-28 Balakrishnan Chakrapani Narmada, Atefeh Khakpoor, Niranjan Shirgaonkar, Sriram Narayanan, Pauline Poh Kim Aw, Malay Singh, Kok Haur Ong, Collins Oduor Owino, Jane Wei Ting Ng, Hui Chuing Yew, Nu Soibah Binte Mohamed Nasir, Veonice Bijin Au, Reina Sng, Nivashini Kaliaperumal, Htet Htet Toe Wai Khine, Francesca Casuscelli di Tocco, Otsuka Masayuki, Shamita Naikar, Hui Xin Ng, Su Li Chia, Cindy Xin Yi
Hepatitis B surface antigen (HBsAg) loss or functional cure (FC), is considered the desirable therapeutic outcome for chronic hepatitis B (CHB) patients. However, the immune-pathological biomarkers and underlying mechanisms remain unclear. In this study we comprehensively interrogate disease-associated cell states (DACS) identified within intra-hepatic tissue and matched PBMCs from either CHB or FC
-
PTEN Deficiency Induces an Extrahepatic Cholangitis-Cholangiocarcinoma Continuum via Aurora kinase A in Mice J. Hepatol. (IF 25.7) Pub Date : 2024-02-28 Yan Yang, Jiale Wang, Jianhua Wan, Qianqian Cheng, Zenong Cheng, Xueli Zhou, Oliver Wang, Kelvin Shi, Lingxiang Wang, Bin Wang, Xiaohui Zhu, Jiaxiang Chen, Dongfeng Feng, Yang Liu, Yasmin Jahan-mihan, Ashley N. Haddock, Brandy H. Edenfield, Guang Peng, Jessica D. Hohenstein, Chantal E. McCabe, Daniel R. O'Brien, Chen Wang, Sumera I. Ilyas, Liuyan Jiang, Michael S. Torbenson, Huamin Wang, Raouf E. Nakhleh
The PTEN-AKT pathway is frequently altered in extrahepatic cholangiocarcinoma (eCCA). We aim to evaluate the role of PTEN in the pathogenesis of eCCA and find novel therapies for this disease. The gene in the biliary epithelial cells were genetically deleted using the Cre-loxp system. The pathologies were evaluated both macroscopically and histologically. The characteristics were further analyzed by
-
Emotional Intelligence: An Impactful Yet Often Overlooked Skill That Can Enhance Physician Well-being and Professional Satisfaction Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-28 David J. Hass, Marc A. Brackett
-
Antibiotic exposure and risk of new-onset inflammatory bowel disease: a systematic review and dose-response meta-analysis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-28 Ruqiao Duan, Cunzheng Zhang, Gaonan Li, Jun Li, Liping Duan
The association between antibiotic exposure and inflammatory bowel disease (IBD) remains controversial, especially whether there is a dose-response relationship. We aimed to conduct a systematic review and meta-analysis to thoroughly evaluate the risk of new-onset IBD associated with antibiotic exposure. Four databases were searched from their inception to September 30, 2023, for all relevant studies
-
GLOBAL PREVALENCE OF PANCREATIC CYSTIC LESIONS IN THE GENERAL POPULATION ON MAGNETIC RESONANCE IMAGING: A SYSTEMATIC REVIEW AND META-ANALYSIS Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-28 Ana Vilela, Elit Quingalahua, Alejandra Vargas, Fadi Hawa, Carol Shannon, Eileen S. Carpenter, Jiaqi Shi, Somashekar G. Krishna, Un-Jung Lee, Jean M. Chalhoub, Jorge D. Machicado
Understanding the burden of pancreatic cystic lesions (PCLs) in the general population is important for clinicians and policymakers. In this systematic review, we sought to estimate the global prevalence of PCLs using magnetic resonance imaging (MRI) and to investigate factors that contribute to its variation. We searched MEDLINE, EMBASE, and Cochrane Central, from database inception through February
-
Defining Endoscopic Remission in Crohn’s Disease: MM-SES-CD and SES-CD Thresholds Associated with Low Risk of Disease Progression Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-28 Neeraj Narula, Emily C.L. Wong, Parambir S. Dulai, Jaiminkumar Patel, John K. Marshall, Clara Yzet, Vipul Jairath, Ryan Ungaro, Jean-Frederic Colombel, Walter Reinisch
We assessed Modified Multiplier Simple Endoscopic Score for Crohn’s disease (MM-SES-CD) and SES-CD thresholds that are best associated with low likelihood of long-term disease progression. Data from 61 patients with early CD who participated in the CALM long-term extension study were used as the derivation cohort and validated using the McMaster IBD database (n=99). The primary outcome was disease
-
Ultra-processed foods and food additives in gut health and disease Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-22 Kevin Whelan, Aaron S. Bancil, James O. Lindsay, Benoit Chassaing
-
Another renaissance for bile acid gastrointestinal microbiology Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-21 Jason M. Ridlon, H. Rex Gaskins
-
Reply to: Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 R. Biallas, R. Zimmermann, S. Dudareva
-
Potential augmentation of terlipressin antidiuretic effects by gabapentinoids J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Penelope N. Markham, Jasmohan S. Bajaj, Paul J. Thuluvath, David Koch, Joseph Palumbo
-
Changing from NAFLD to MASLD: The implications for health-related quality of life data J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Ryuki Hashida, Dan Nakano, Machiko Kawaguchi, Zobair M. Younossi, Takumi Kawaguchi
-
“Autoimmune Hepatitis: Azathioprine or Mycophenolate Mofetil for inducing remission?” J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Avinash Tiwari, Duncan Khanikar, Santosh Govind Rathod
-
CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Peiyi Xie, Mincheng Yu, Bo Zhang, Qiang Yu, Yufei Zhao, Mengyuan Wu, Lei Jin, Jiuliang Yan, Binghai Zhou, Shuang Liu, Xiaoqiang Li, Chenhao Zhou, Xiaodong Zhu, Cheng Huang, Yongfeng Xu, Yongsheng Xiao, Jian Zhou, Jia Fan, Mien-Chie Hung, Qinghai Ye, Lei Guo, Hui Li
Immune checkpoint inhibitors (ICIs) resistance limits immunotherapy success in hepatocellular carcinoma (HCC). However, the mechanisms underlying immunotherapy resistance remain elusive. We aimed to identify the role of CT10 regulator of kinase-like (CRKL) in HCC against anti-PD-1 therapy. Gene expression in HCC specimens from 10 patients accepted anti-PD-1 therapy was identified by RNA-sequencing